ArticleAmerican journal of cancer research2026
Matrine enhances RLS3-induced ferroptosis at non-toxic doses in acute myeloid leukemia cells with MLL rearrangement.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leukemia with MLL rearrangement (MLL-r) always exhibited a poor prognosis. Targeting ferroptosis was believed to be a novel strategy for the treatment of leukemia. However, the ferroptosis inducer, RSL3 (GPX4 inhibitor), was not clinically available due to its potential off-target effects and toxicity. This study aimed to explore whether the additional matrine (MAT) could yield superior therapeutic outcomes with ferroptosis inducer. Herein, we explored that MAT can synergistically induce ferroptosis with non-toxic dosage of RSL3 in MOLM-13 and MV4-11 cells. The underlying mechanism was investigated via western blot, quantitative RT-PCR (qRT-PCR) analysis, enzyme-linked immunosorbent assay (ELISA) and Flow cytometry. We found that the combination of MAT and non-toxic-dose RSL3 significantly increased levels of intracellular ferrous ion (IFI) and lipid ROS, decreased mitochondrial membrane potential and glutathione (GSH) levels, as well as down-regulated the expression of SLC7A11 and GPX4. Systematic bioinformatic analysis results have indicated that MAT may potentiate the efficacy of RSL3 through modulation of the p53 signaling pathway. Further experiments showed that knocking down p53 reduced the synergistic effect of MAT and RSL3 in inducing ferroptosis. In addition, the combination of MAT and RSL3 can dramatically reduce the population of bone marrow CD45+ cells in AML xenograft mouse. In conclusion, MAT can synergistically promote non-toxic-dose RSL3 induced ferroptosis by modulating the p53 pathway in AML with MLL translocation, which may potentially enable the clinical application of ferroptosis inducers in further.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.